These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 8109659)
1. Long-term follow-up of 85 patients with obsessive-compulsive disorder. Orloff LM; Battle MA; Baer L; Ivanjack L; Pettit AR; Buttolph ML; Jenike MA Am J Psychiatry; 1994 Mar; 151(3):441-2. PubMed ID: 8109659 [TBL] [Abstract][Full Text] [Related]
2. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder. Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953 [TBL] [Abstract][Full Text] [Related]
3. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder. Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069 [TBL] [Abstract][Full Text] [Related]
4. Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo. Stein DJ; Andersen EW; Overo KF Braz J Psychiatry; 2007 Dec; 29(4):303-7. PubMed ID: 18200396 [TBL] [Abstract][Full Text] [Related]
5. Obsessive-compulsive disorder: a 3-year prospective follow-up study of patients treated with serotonin reuptake inhibitors OCD follow-up study. Catapano F; Perris F; Masella M; Rossano F; Cigliano M; Magliano L; Maj M J Psychiatr Res; 2006 Sep; 40(6):502-10. PubMed ID: 16904424 [TBL] [Abstract][Full Text] [Related]
6. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922 [TBL] [Abstract][Full Text] [Related]
7. Adults with early-onset obsessive-compulsive disorder. Rosario-Campos MC; Leckman JF; Mercadante MT; Shavitt RG; Prado HS; Sada P; Zamignani D; Miguel EC Am J Psychiatry; 2001 Nov; 158(11):1899-903. PubMed ID: 11691698 [TBL] [Abstract][Full Text] [Related]
8. Effects of selective serotonin reuptake inhibitors on thought-action fusion, metacognitions, and thought suppression in obsessive-compulsive disorder. Besiroglu L; Çetinkaya N; Selvi Y; Atli A Compr Psychiatry; 2011; 52(5):556-61. PubMed ID: 21109243 [TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy. Alonso P; Menchon JM; Pifarre J; Mataix-Cols D; Torres L; Salgado P; Vallejo J J Clin Psychiatry; 2001 Jul; 62(7):535-40. PubMed ID: 11488364 [TBL] [Abstract][Full Text] [Related]
11. Increased maintenance of obsessive-compulsive disorder remission after integrated serotonergic treatment and cognitive psychotherapy compared with medication alone. Biondi M; Picardi A Psychother Psychosom; 2005; 74(2):123-8. PubMed ID: 15741763 [TBL] [Abstract][Full Text] [Related]
12. Citalopram in refractory obsessive-compulsive disorder: an open study. Marazziti D; Dell'Osso L; Gemignani A; Ciapparelli A; Presta S; Nasso ED; Pfanner C; Cassano GB Int Clin Psychopharmacol; 2001 Jul; 16(4):215-9. PubMed ID: 11459335 [TBL] [Abstract][Full Text] [Related]
13. Higher serotonin transporter availability in early-onset obsessive-compulsive disorder patients undergoing escitalopram treatment: A [ Lee J; Kim BH; Kim E; Howes OD; Cho KIK; Yoon YB; Kwon JS Hum Psychopharmacol; 2018 Jan; 33(1):. PubMed ID: 29210107 [TBL] [Abstract][Full Text] [Related]
14. Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse. Hollander E; Stein DJ; Fineberg NA; Marteau F; Legault M J Clin Psychiatry; 2010 Jun; 71(6):784-92. PubMed ID: 20492845 [TBL] [Abstract][Full Text] [Related]
15. Clinical predictors of response to pharmacotherapy with selective serotonin reuptake inhibitors in obsessive-compulsive disorder. Tükel R; Bozkurt O; Polat A; Genç A; Atli H Psychiatry Clin Neurosci; 2006 Aug; 60(4):404-9. PubMed ID: 16884439 [TBL] [Abstract][Full Text] [Related]
16. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study. Li X; May RS; Tolbert LC; Jackson WT; Flournoy JM; Baxter LR J Clin Psychiatry; 2005 Jun; 66(6):736-43. PubMed ID: 15960567 [TBL] [Abstract][Full Text] [Related]
17. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. Weiss EL; Potenza MN; McDougle CJ; Epperson CN J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634 [TBL] [Abstract][Full Text] [Related]
18. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder. Koran LM; Aboujaoude E; Gamel NN J Clin Psychiatry; 2009 Nov; 70(11):1530-5. PubMed ID: 19573497 [TBL] [Abstract][Full Text] [Related]
19. Metacognitive beliefs predict early response to pharmacological treatment in patients with obsessive-compulsive disorder. Park CI; Kim HW; Jeon S; Hwang EH; Kang JI; Kim SJ Psychopharmacology (Berl); 2020 Nov; 237(11):3489-3496. PubMed ID: 32748029 [TBL] [Abstract][Full Text] [Related]